1-20 of 250
Alessandra Ferrajoli, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

Koji Sasaki, MD, Elias Jabbour, MD, Kiran Naqvi, MD MPH, Jeffrey Skinner, MHA, Kristin Anderson, Sara E Dellasala, BS, Musa Yilmaz, MD, Alessandra Ferrajoli, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD PhD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Rita Khouri, Shilpa Paul, PharmD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-140003
Published: 2020
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-141014
Published: 2020
Journal Articles

Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL)

Veronica A Guerra, MD, Yasmin Alwash, MD, Yan Yuanqing, PhD, Jorge M. Ramos Perez, MD, Guillaume Richard-Carpentier, MD, Ahmad S. Alotaibi, MD, Hycienth O Ahaneku, MD MPH, PhD, Bachar Samra, MD, Arrvind Raghunath, MD, Nitin Jain, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Koji Sasaki, MD, Steven M. Kornblau, MD, Zeev E. Estrov, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-142055
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3 mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Guillermo Montalban-Bravo, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn S Montalbano, RN, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Naval Daver, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–55.
https://doi.org/10.1182/blood-2020-137822
Published: 2020
Journal Articles

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Jade Jones, MD, Binsah Susan George, MD, Christine B Peterson, Thao-Mi Tran Ha, Jan A. Burger, MD PhD, Nitin Jain, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Jean-Bernard Durand, MD, Alessandra Ferrajoli, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-141284
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R Brown, MD PhD, John C. Byrd, MD, Paolo Ghia, MD PhD, Jeff P Sharman, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Deborah M. Stephens, DO, Clare Sun, MD, Wojciech Jurczak, John M. Pagel, MDPhD, Alessandra Ferrajoli, MD, Priti Patel, MD, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, MD, Javid J. Moslehi, MD, Richard R. Furman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–54.
https://doi.org/10.1182/blood-2020-134797
Published: 2020
Journal Articles

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD, Nadya Jammal, PharmD, Shilpa Paul, PharmD, Xuemei Wang, MS, Koji Sasaki, MD, Philip A. Thompson, MB, MS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Nitin Jain, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135938
Published: 2020
Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Patrick K Reville, MD, Graciela M. Nogueras González, MPH, Farhad Ravandi, MBBS, Koji Sasaki, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141837
Published: 2020
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine

Abhishek Maiti, MBBS, Sergej Konoplev, MD PhD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Yesid Alvarado, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-138580
Published: 2020
Journal Articles

Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials

Kunhwa Kim, MDMPH, Marina Konopleva, MD PhD, Courtney D. DiNardo, MD MSCE, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Elias Jabbour, MD, Steven M. Kornblau, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Alessandra Ferrajoli, MD, Nitin Jain, MD, Nicholas J. Short, MD, Caitlin R. Rausch, PharmD, Mark Brandt, BS, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-142041
Published: 2020
Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koji Sasaki, MD, Ghayas C. Issa, MD, Maro Ohanian, DO, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Kapil N. Bhalla, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Koichi Takahashi, MD PhD, Rashmi Malla, RN, BSN, Kelly Marek, Mark Brandt, BS, Uday R. Popat, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-142092
Published: 2020
Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Curtis Lachowiez, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Sanam Loghavi, MD, Sa A Wang, MD, Maria Adeoti, R.N., Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD PhD, Nicholas J. Short, MD, Koji Sasaki, MD, Gautam Borthakur, MD, Ghayas C. Issa, MD, William G. Wierda, MD PhD, Naveen Pemmaraju, MD, Guillermo Montalban Bravo, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Lucia Masarova, MD, Musa Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134300
Published: 2020
Journal Articles

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Lucia Masarova, MD, Jan A. Burger, MD PhD, Philip A. Thompson, MB, MS, Srdan Verstovsek, MD PhD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-138773
Published: 2020
Journal Articles

Outcomes of TP53 -Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

Kunhwa Kim, MDMPH, Abhishek Maiti, MBBS, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Yesid Alvarado, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–36.
https://doi.org/10.1182/blood-2020-140182
Published: 2020
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019